How should we assess CV risk in 2026?
On Demand
How should we assess CV risk in 2026? — Recording
How it works
- 1Watch the full recording — you cannot skip ahead
- 2Answer 3 short clinical reflection questions
- 3Your CPD certificate is unlocked instantly
About This Webinar
Traditional cardiovascular risk assessment no longer tells the whole story. This session looks at how genetics, genomics and Lp(a) help identify high-risk patients in primary care, covering how to diagnose Familial Hypercholesterolaemia, the role of polygenic risk, and what Lp(a) reveals about an individual’s CV risk.
Learning Objectives
- Explain the limitations of traditional CV risk tools and the role of genetics, genomics and Lp(a).
- Identify the clinical features of Familial Hypercholesterolaemia and the referral and cascade testing pathways.
- Distinguish Familial from polygenic hypercholesterolaemia, and describe what polygenic risk means in CVD.
- Define Lp(a) and explain when measuring it adds value to CV risk assessment.
What this on-demand session covers
This on-demand CPD session helps primary-care clinicians assess cardiovascular risk beyond traditional tools. It covers familial hypercholesterolaemia, genetics and polygenic risk, lipoprotein(a), and how these findings can inform referral and management discussions.
Explore related evidence
Read the Medicine Central evidence that supports the clinical themes covered in this session.
Speakers
Prof Ahmet Fuat, PhD, FRCGP, FRCP, FRCPE, FESC, FPCCS
Clinical expertise: Prof Ahmet Fuat is a GP and world renowned recognised cardiology educator with expertise in cardiovascular disease, cardiorenal medicine and lipid management in primary care.